eEML - Electronic Essential Medicines List

General description

INN

Vincristine

ATC codes

Medicine type

Chemical agent

EML status history

First added in 1977 (TRS 615) for Unspecified malignant neoplasms of unspecified sites

Changed in 2011 (TRS 965) for Malignant neoplasms of kidney, except renal pelvis

Changed in 2011 (TRS 965) for Lymphoid leukaemia, not elsewhere classified

Changed in 2011 (TRS 965) for Burkitt lymphoma including Burkitt leukaemia

Changed in 2015 (TRS 994) for Rhabdomyosarcoma primary site

Changed in 2015 (TRS 994) for Diffuse large B-cell lymphoma, not otherwise specified

Changed in 2015 (TRS 994) for Malignant trophoblastic neoplasms of placenta

Changed in 2015 (TRS 994) for Hodgkin lymphoma

Changed in 2015 (TRS 994) for Kaposi sarcoma of unspecified primary site

Changed in 2015 (TRS 994) for Retinoblastoma

Changed in 2015 (TRS 994) for Follicular lymphoma

Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of unspecified sites

Added in 2021 (TRS 1035) for Other specified gliomas of brain

Changed in 2023 (TRS 1049) for Langerhans cell histiocytosis

Wikipedia

DrugBank

Recommendations

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 2 mg per 2 mL in vial (vincristine sulfate); 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate)
Parenteral > General injections > IV: 5 mg in vial (vincristine sulfate); 1 mg in vial (vincristine sulfate)

Indications

Export